SRTAHealthcare · Medical Care Facilities

SRTA Stock Forecast: Strata Critical Medical, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$5.34

−0.74% on the day

The 4 Wall Street analysts covering Strata Critical Medical, Inc. hold a median 12-month price target of $8.75 — +63.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 19 Sept 2026 — in the lower half.

Market cap

$476.0M

Ticker Nerd rank

47 / 100

Median analyst target

$8.75

Analysts covering

Revenue$72.5M+2.4% y/y

Operating income−$5.4M

Net income−$10.5M

Free cash flow$2.9M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+2.8%

−6.3%

YTD

+11.0%

−8.4%

From 52W high

−17.5%

From 52W low

+32.5%

$4.03

$6.47

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SRTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Strata Critical Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Revisions

Issuance

Size

Growth

Quality

Value

Volatility

Accruals

Momentum (76): The shares have been drifting up relative to others.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts

4 Buy0 Hold0 Sell

Low $8.00Median $8.75High $12.75

The green dot is the last close — the median target sits +63.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
25 Mar 2026	B. Riley Securities	Initiates	Buy	$8.00
25 Mar 2026	Craig-Hallum	Initiates	Buy	$8.00
2 Dec 2025	Lake Street	Assumes	Buy	$8.00
17 Sept 2025	Lake Street	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRTA appears on the weeks it earns a place.

Performance

SRTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Strata Critical Medical, Inc. returned −8.4% against +16.3% for the S&P 500, dividends included.

SRTA vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Strata Critical Medical, Inc. (SRTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 11.1×
Price / sales: 1.8×
Price / book: 1.7×
EV / EBITDA: 63.3×

Growth & margins

Revenue growth (YoY): 60.7%
Earnings growth (YoY): 2.4%
Gross margin: 21.0%
Operating margin: −6.3%
Net margin: 15.7%

Returns & dividend

Return on equity: −9.2%
Return on assets: −1.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Strata Critical Medical, Inc. (SRTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Strata Critical Medical, Inc. has a market value of $476.0M and an enterprise value of $457.5M.
Revenue in the twelve months to 30 June 2026: $256.0M. The latest quarter grew 60.7% year on year.
Net income over the same four quarters: $40.2M, a 15.7% net margin.
Diluted earnings per share, trailing twelve months: $0.51.
Free cash flow in the twelve months to 30 June 2026: −$49.5M, after $1.1M of capital spending.
Shares outstanding: 88.5M.
Trailing P/E: 11.1×; forward P/E: 1582.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Strata Critical Medical, Inc. employs 327 people — $783K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

SRTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities

Company	Market cap	TKN rank
SRTAStrata Critical Medical, Inc.	$476.0M	47
CYHCommunity Health Systems, Inc.	$397.6M	68
AUNAAuna SA	$377.5M	53
GMRSGMR Solutions, Inc.	$676.8M	1
STLNStarling Oncology, Inc.	$684.7M	63
USPHU.S. Physical Therapy, Inc.	$1.3B	51
AIRSAirSculpt Technologies, Inc.	$163.0M	51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Strata Critical Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRTA news & analysis

Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference

GlobeNewsWire · 8 Sept 2026neutral

Strata Critical Medical, Inc. (Nasdaq: SRTA) announced that its management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available, and a replay will be posted on the investor relations section of the company's website after the presentation concludes.

Why it matters — The presentation gives SRTA watchers a chance to hear directly from company management at a prominent healthcare industry conference, which may provide insight into the company's current positioning.

Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 24 Aug 2026positive

Strata Critical Medical, Inc. (SRTA) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher on improved earnings expectations.

Why it matters — A SRTA watcher would care because the upgrade signals improved earnings prospects and increased analyst confidence in the company.

Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?

Zacks Investment Research · 24 Aug 2026positive

Zacks Research reports that the mean of Wall Street analysts' price targets for Strata Critical Medical, Inc. (SRTA) implies roughly 47.3% upside in the stock. The article notes that while price-target metrics have not proven consistently effective, strong analyst agreement in raising earnings estimates points to potential upside for SRTA.

Why it matters — A SRTA watcher would care because it highlights that analysts are revising earnings estimates upward, which could signal improving expectations for the company's prospects.

Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?

Zacks Investment Research · 6 Aug 2026positive

Zacks reports that Strata Critical Medical, Inc. (SRTA) shares have started gaining and, based on solid earnings estimate revisions, might continue moving higher in the near term.

Why it matters — A SRTA watcher would care because the improved earnings estimates point to a possible continuing upward trend in the stock.

Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know

Zacks Investment Research · 4 Aug 2026positive

The consensus price target for Strata Critical Medical, Inc. (SRTA) hints at 60% upside potential. While research shows this measure is not highly effective, an upward trend in earnings estimate revisions suggests the stock could see near-term upside.

Why it matters — SRTA watchers would note the analyst consensus price target and the upward trend in earnings estimate revisions as indicators of possible near-term stock movement.

FAQ

Frequently asked questions about SRTA stock

What is the SRTA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Strata Critical Medical, Inc. have a median 12-month price target of $8.75, with estimates ranging from $8 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRTA stock a buy right now?

Of the 4 analysts covering Strata Critical Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Strata Critical Medical, Inc. 47 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRTA?

As at 19 Sept 2026, Strata Critical Medical, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (76 of 100).

Will SRTA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +63.9% from the last close, and Ticker Nerd's factor model ranks Strata Critical Medical, Inc. 47 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRTA stock forecast for 2030?

No analyst covering Strata Critical Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $13 over the next 12 months.

How has SRTA stock performed over the past year?

Strata Critical Medical, Inc. returned -8.4% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Strata Critical Medical, Inc. do?

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States.

What is the latest news on SRTA?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference". Strata Critical Medical, Inc. (Nasdaq: SRTA) announced that its management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available, and a replay will be posted on the investor relations section of the company's website after the presentation concludes.

Company

About Strata Critical Medical, Inc.

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

CEO Ms. Melissa M. Tomkiel J.D. · 327 employees · United States · https://www.stratacritical.com